Invivo Therapeutics Holdings Corp (NVIV) : Ims Capital Management scooped up 23,533 additional shares in Invivo Therapeutics Holdings Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 270,499 shares of Invivo Therapeutics Holdings Corp which is valued at $1,622,994.Invivo Therapeutics Holdings Corp makes up approximately 1.96% of Ims Capital Management’s portfolio.
Invivo Therapeutics Holdings Corp opened for trading at $6.07 and hit $6.15 on the upside on Monday, eventually ending the session at $6.11, with a gain of 1.83% or 0.11 points. The heightened volatility saw the trading volume jump to 2,34,316 shares. Company has a market cap of $169 M.
Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa sold out all of its stake in NVIV during the most recent quarter. The investment firm sold 2,660 shares of NVIV which is valued $16,253. Simplex Trading sold out all of its stake in NVIV during the most recent quarter. The investment firm sold 1,331 shares of NVIV which is valued $8,572.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.